BioSpace News Archive

First Reported E3 Ligase Beyond Cereblon and VHL Shown to Support Broad Targeted Protein Degradation of Multiple Targets In Vivo [15-May-2020] SAN DIEGO , May 15, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced data des

Preclinical data suggests multiple mechanisms of action for SM-88, including an increase in reactive oxygen species, alterations in autophagy and immunomodulation Preclinical data for TYME-18, an intra-tumoral delivered therapy, displayed statistically significant anti-cancer effects in animal cancer models, including the complete resolution of a majority of tumors Lead pipeline investigational compound, SM-88, represents a new approach designe

Preclinical and biomarker research data will be reported for U3-1402 (HER3 DXd ADC) in HER3 expressing cancers including combination with osimertinib in EGFR mutated NSCLC Presentations for several of Daiichi Sankyo’s DXd ADCs highlight potential for further expansion of clinical development program to new targets and tumor types BASKING RIDGE, N.J. & MUNICH--( BUSINESS WIRE )-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo

Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary data from 9 ambulatory boys with DMD, aged 6 to 12 (mean age: 8 years) indicate that the intravenous administration of PF-06939926 was well-tolerated during the infusion period, with encouraging efficacy and manageable safety events, eve

LAIX Inc. (“LAIX” or the “Company”) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced that Ms. Min (Jenny) Zhang has been appointed as an independent director to the Company’s board of directors (the “Board”), effective May 15, 2020

Significant Test Manufacturing Capacity, Large Installed Base of Automated Instruments Yield Testing Breakthrough --

Silverback Therapeutics™ (“Silverback”), a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active, today announced that preclinical data supporting development of its lead ImmunoTAC™ candidate, SBT6050, has been a

HiFiBiO Therapeutics will take a pioneering approach to clinical development of its pipeline of antibody candidates by using patient stratification biomarkers identified by the company’s proprietary Drug Intelligent Science (DIS™) CAMBRIDGE, Mass. & SHANGHAI & PARIS--( BUSINESS WIRE )-- Scientists at HiFiBiO Therapeutics have generated preclinical data packages for novel monoclonal antibodies that demonstrate favorable clinical development

Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation of new data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II , taking place f

Beyond Air, Inc. announced that it has entered into a new common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC, a Chicago-based fundamentally focused, long-term institutional investor, for up to $40 million.